Background: Immunostimulatory monoclonal antibodies (imAbs) targeting immune checkpoint molecules are revolutionizing oncology not only regarding cancer therapeutics and clinical care, but also from a drug development point of view. A handful of first-generation molecules have been approved so far based on their tremendous efficacy, after an expedited development phase that has challenged most paradigms established in the era of conventional cytotoxic therapy and to some extent molecularly targeted agents. A huge wave of second-generation imAbs is just entering into phase 1 trials now, in monotherapy or in combination. In order to maximize their chances of success in early phase trials, and eventually for patients' benefit, their clinical development has to benefit from lessons learnt from previous imAbs phase 1 trials.
these immunostimulatory monoclonal antibodies (imAbs) are now tested in combination studies [12] [13] [14] .
As a consequence of these positive results, the number of imAbs targeting immune checkpoints that are currently developed is exponentially increasing [15] . The anti-CTLA-4 and anti-PD-1/PD-L1 experience has evidenced very specific challenges of phase 1 imAbs trials. It is of crucial importance to appropriately face and address these challenges in order to ensure a successful development of these next-generation imAbs.
ImAbs represent the second biggest paradigm shift in oncology of the last 15 years. The first revolution was the advent of molecularly targeted therapies, directed against tumour cells, which resulted in impressive responses and clinical benefit in appropriately molecularly selected tumours. At that time, the phase 1 world had to adapt from the traditional 'one-size-fits-all' strategy to 'biomarker-driven' trials, where patient selection played a key role. This approach allowed an accelerated and successful development of several agents, including olaparib, crizotinib and ceritinib [16] [17] [18] [19] . Now, early phase specialists are facing an even more challenging task with the advent of imAbs. Beyond the consideration that some oncologists might need to go back to their immunology textbooks, several traditional drug development dogmas will have to be eventually modified to best adapt to these immune-targeted agents. Indeed, imAbs are targeting (and exploiting) the antitumour activity of the patient's immune system. They are targeted therapies by design, but are directed against immunomodulatory molecules expressed at the surface of immune and tumour cells. The efficacy and duration of responses reveal that, at least in some patients, our therapeutic strategies should care less about the isolated cancer cell and its genomic alterations but focus on immune tolerance. Combination therapy may be needed to overcome resistance to single agent immunotherapy [13] , but these may rapidly turn too toxic in humans with standard drug development. New clinical research methodology is, therefore, highly needed to identify safe synergistic combinations. Such methodology notably includes dose recommendation, selection of the most appropriate schedule and route of administration, patient selection, efficacy assessment and choice of the optimal trial design.
Overall, in a context where the impressive efficacy of imAbs has been demonstrated, it is of highest importance to best redesign phase 1 trials and customize them to fulfil the specific requirements of these new agents, and eventually optimize and expedite their development.
challenge 1: safety and maximum tolerated dose definition
The primary end point of phase 1 trials is traditionally to determine the safety, tolerability and recommended phase 2 dose (RP2D) of novel agents for further studies. This is usually obtained through a dose escalation of an experimental drug, following the hypothesis that there is a linear or proportional relationship between dose, efficacy and toxicity. ImAbs challenge these traditional drug development processes, as best illustrated by two features that strikingly show up when recapitulating the recent phase 1 trials of imAbs: first, the inability of almost all trials to identify a maximum tolerated dose (MTD), and second, the huge variety of doses and schedules that have been evaluated upfront.
dose-limiting toxicities and MTD definition
Among the 13 main phase 1 trials of monotherapy imAbs targeting PD-1/-L1 and CTLA-4 (Table 1) [3] [4] [5] [6] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , only one trial identified per-protocol defined dose-limiting toxicities (DLTs) [24] . For most trials, the RP2D determination was based on the maximum administered dose (MAD; 10 trials) or pharmacokinetic (PK) data (2 trials). Another trial [25] identified four lateonset DLTs that were not subsequently taken into account in the dose recommendation process. As with the 3 + 3 dose-escalation method, the targeted proportion of DLTs is 17%-33% of patients; this absence of MTD identification is in line with the low rates of G3/4 toxicities (∼13%) reported in expansion cohorts [6, 28] . Interestingly, imAbs seem to have limited potential for causing acute or cumulative toxicities (besides anaphylactoid infusion reactions): drug-related toxicities are usually not observed during the first cycle and immune-related adverse events (irAEs) have been reported at any later time on trial. For example, irAEs classically appear 8-10 weeks after starting ipilimumab, whatever the grade [31] . As irAEs can rapidly become life-threatening if not optimally managed promptly according to dedicated guidelines [3, 32, 33] , most protocols now recommend holding the drug until toxicity recovery (and then resuming it) as soon as Grade 2 (G2) irAEs (i.e. 'moderate' AEs) are diagnosed. Although such AEs are not considered as DLTs, they lead to a decreased drug exposureand thereby diminished relative dose intensity-and should therefore score as DLTs [34, 35] . Consequently, a DLT definition taking into account only G3-4 events occurring during the first cycle may not be appropriate. If the DLT period should not be lengthened in order to allow rapid dose escalation, toxicities scoring as DLTs observed beyond cycle 1 should be thoroughly considered during dose recommendation. Also, in cases where no MTD is identified, or where a saturation phenomenon is observed above a certain dose in pharmacodynamic (PD) and PK parameters, a dose recommendation based on PK/PD should be encouragedpotentially as the form of a fixed dose if relevant.
Interestingly, most imAbs phase 1 trials have used predefined dose-escalation levels including a maximum feasible dose in case no MTD was identified. Also, two of the most recent trials have lengthened the DLT period to two cycles [4, 30] . Although toxicity appears to be relatively dose-dependent for anti-CTLA-4 imAbs (Table 1) , higher doses of these agents do not result in higher objective responses rates (ORRs) ( Table 2 ) [31] . On the other hand, anti-PD-1/PD-L1 antibodies have no clear correlation between dose, efficacy and toxicities, as responses and AE rates seem equivalent beyond 1-2 mg/kg and up to 20 mg/kg either q2 or q3w [3, 4, 6, 26, 27] . This overall absence of DLTs and relatively safe profile of imAbs suggest that alternative designs, such as modified toxicity probability interval design [40] , may be more appropriate. This design allows targeting a large range of DLT rates, including those below 17%, and including some flexibility in the number of patients exposed to a given dose, thereby resulting in a higher accuracy in estimating the DLT rate at each dose and the possibility of larger cohorts.
The safety profile of immune checkpoint blockade imAbs might be completely different from that of agonistic immune checkpoint antibodies though. The unfortunate experience of the cytokine release syndrome developed upon TGN1412 anti-CD28 agonistic antibody therapy developed by TeGenero is an (6) illustration of how toxic these latter can be [41] . However, the recent publication of the first anti-OX40 and anti-CD137 agonistic mAb phase 1 trials has demonstrated that other stimulatory immune checkpoints can be developed safely in humans [42, 43] .
optimal dose and schedule selection
The second striking characteristic of phase 1 trials evaluating imAbs is the difficulty in determining the appropriate dose and schedule. Among the 13 above-cited trials, six trials evaluated a • 0.3-10 mg/kg q2w for up to 16 cycles (6-weeks cycles)
• Accelerated titration design followed by a 3 + 3 dose-escalation design single dose (followed by a potential rechallenge with the drug at 3 months for one trial) [5, [20] [21] [22] [23] [24] 27] . Other trials evaluated various schedules, including repeated drug administrations on D1/3/5 [43] , or q2, q3 or q4 weeks and up to q3 months [44, 37] with or without any pre-defined maximal number of cycles. Of note, no consistent pattern could be found according to the IgG isotype and the tested frequencies of administration. This challenge is well illustrated by ipilimumab's development: although the drug was evaluated in several phase 1 trials [20, 22, 23] , it was subsequently studied at multiple doses and schedules in later phase trials. Three dose levels were compared in a phase 2 trial in MM (0.3, 3 and 10 mg/kg [36] q3w for four cycles), and patients with disease control could receive maintenance treatment q12w. The ORR seemed to increase with the dose (0%, 4.2% and 11.1% for each group, respectively; trendtest P = 0.002), but this was not confirmed in larger cohorts [1, 10, 45] . Although the approved dose of ipilimumab is 3 mg/kg q3w [1] , one phase 3 trial evaluated ipilimumab at doses of 10 mg/kg for four doses followed by maintenance (10 mg/kg q12w) [2] and both doses are currently being compared in a randomized phase 3 study (NCT01515189). For anti-PD-1 antibodies, little efficacy can be expected below 1 mg/kg, but ORR do not differ across doses and schedules between 2 and 10 mg/kg and q2w to q3w [36, 38, 46] . Several doses (between 1 and 3 mg/kg) and regimens (sequential versus concomitant) have been tested for the combination of nivolumab and ipilimumab [13, 14, 47] .
Altogether, this broad variety of administration schedules and doses probably evidences one of the current most difficult questions: should imAbs be considered as 'targeted therapieslike' agents, for which is it key to maintain a permanent pressure of selection (i.e. the immune system activation in this case) through continuous therapy? Or should imAbs be considered as 'vaccines', for which one first-dose administration, followed by a limited number of boosters, would be sufficient to trigger a durable immune response? The fact that tumour responses can be obtained with imAb rechallenge in secondary refractory patients [45] may support the development of discontinuous schedules, in order to improve the patient's quality of life, and to minimize the future economic costs of such therapies.
challenge 2: trial design and expansion cohorts
There is a stark contrast between the number of patients included in the original ipilimumab studies (9-46 patients) and the current number of enrolled patients, which overcomes a thousand patients for some ongoing trials [48] . This nicely illustrates the switch observed over the past 3-5 years in phase 1 trials, secondary to the emergence of early molecular patient selection and search for breakthrough designation, accelerated or conditional approval by the health regulatory authorities [18, 19, 49] . This laudable and valuable early enrichment strategy has allowed considerably reducing the development time from phase 1 to registration for undoubtedly active drugs, as illustrated by the successful crizotinib or ceritinib stories [18, 19] . Phase 1 trials of imAbs are currently following this route (NCT01375842 and NCT01295827).
This counteracts and precipitates the traditional drug development steps. Historically, phase 1 studies were dedicated to identify the MTD and RP2D. Then, phase 2 trials allowed assessing drug efficacy, and in case of efficacy, a randomized phase 3 trial would have compared the historical treatment to the investigational one in order to demonstrate its added value and legitimate registration for commercialization. The development of pembrolizumab has inaugurated a new paradigm of drug development where large expansion cohorts are directly added to the phase 1 study, with multiple dosage and histotypes tested in parallel ( Figure 1 ). This directly follows the route of the 'molecular enrichment' drug development strategy that was used for some molecularly targeted therapy and basket studies. The role of these expansion cohorts has been clearly to demonstrate treatment efficacy, an end point that has never been officially used in phase 1 trials. The current development of agonistic imAbs is now following this model. The advantage of such strategy is obviously to shorten the drug development duration. With hundreds of patients treated in its expansion cohorts and good efficacy data, pembrolizumab received an FDA breakthrough designation therapy, which allowed its commercialization <4 years after the beginning of the phase 1 trial [26] , whereas the average development time for a drug to be approved was historically around 10 years.
However, justification of the sample size and primary objective of the expansion cohorts should be provided whenever feasible. Also, stopping rules for non-efficacy should be prespecified when expansion cohorts enrol patients beyond what is sufficient for PK/PD analyses, and are obviously designed to assess efficacy. Indeed, the parallel opening of multiple expansion cohorts of unlimited number of patients without any clear toxicity, PK/PD or translational studies objectives exposes to the risk of unethical treatment at inadequate doses of a high number of patients.
Results from such cohorts should be optimally exploited to best prepare later large randomized registration trials.
challenge 3: patient selection, biomarkers and personalized medicine
With the identification of tumour-specific antigens and somatic mutations, tumour-targeted therapies have inaugurated the era of predictive biomarkers of response and personalized medicine.
Immune-targeted therapies have demonstrated that 'fixed' and 'dynamic' biomarkers should be distinguished. Despite tumour heterogeneity, and without a therapeutic selection pressure, tumour-specific targets (such as HER2 amplifications, EGFR mutations, ALK translocation, BRAF mutation etc.) are considered to be stable over time. They can be assessed at a protein or DNA level using robust identification tests. PD-L1 expression is mostly inducible and can quickly vary over time in response to cytokines in the microenvironment. Moreover, thresholds to consider its positivity, techniques used (antibodies, assays) and cells on which this biomarker should be assessed are not consensual 
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Approval P1 P1 Figure 1 . The evolving landscape of phase 1 trials-from cytotoxics to immunostimulatory moloclonal antibodies (imAbs). Many changes have been observed in the landscape of phase 1 trials since the era of cytotoxic chemotherapy. Trials have moved from enrolling a small number of unselected patients to several hundreds of appropriately selected patients' large expansion cohorts. In parallel, the route of administration has evolved as well as the toxicity profile-most recent trials do not reach the maximum tolerated dose, which is replaced by the maximum administered dose (MAD). For agents that do not display a linear dose-efficacy relationship, pharmacodynamics (PD) and pharmacokinetics (PK) have also played an increasingly important role, notably in helping determining the optimal biological dose (OBD) for targeted agents. Whether, by analogy to the OBD, an optimal immunological dose (OID) based on PK and PD data of immunological monitoring could be used for imAbs warrants further exploration. Clinical trial designs have evolved in parallel, in order to maintain a rapid dose-escalation phase and expand in large selected cohorts or hundreds of patients in order to achieve the proof-of-concept and provide robust activity data as early as phase 1. Consequently, phase 1 trials have been gradually replaced by phase 1-2 trials, and very recent conditional approvals have even been granted based on the results of large phase 1 expansion cohorts, thereby by-passing the traditional phase 2 trials, and the phase 1/2/3 traditional model. All these evolutions have allowed dramatically reducing the drug development time from >10 years to <5 years between the first-in-man administration and the drug registration, for patients' benefit. #, number; IV, intravenous; MAD, maximum administered dose; MTD, maximum tolerated dose; OBD, optimal biological dose; OID, optimal immunological dose; P1, phase 1; P2, phase 2; P3, phase 3; PD, pharmacodynamics; PK, pharmacokinetics. yet. Although the positivity of the PD-L1 status, both on tumour [3, 4] and tumour-infiltrating immune cells [28] , has been significantly correlated with response in MM and NSCLC [9, 47] , therapeutic benefit has also consistently been reported in PD-L1-negative patients [7, 8, 11] . Additional baseline biomarkers, such as CTLA-4 or fractalkine, may bring additional information [28] . PD-L1 expression modification on treatment has also been evaluated: if PD-L1 upregulation has significantly been associated with response, the absence of upregulation has been associated with the lack of response-potentially secondary to immunological ignorance, non-functional immune response or excluded infiltrates [28] . Very interestingly, the correlation between PD-L1 expression and response to anti-PD-1/PD-L1 has been detected on samples that were sometimes collected several years before starting imAb treatment, and in patients who had received cytotoxics or targeted therapy between the time of the biopsy and C1D1 of immunotherapy [4] . This suggests a degree of stability of the immune surveillance, but might also be dependent on the type of previous treatment received [50] . Immunological monitoring of several blood-based biomarkers (including IL-18, interferon inducible T-Cell alpha chemoattractant, INF-γ and activated CD8+ T-cell monitoring) has been examined, but no correlation with drug sensitivity has been evidenced yet. The use of adaptive phase 1 trial designs has allowed this impressive profusion of predictive biomarker studies. These now require prospective validation in phase 3 trials. Results from studies carried out in unselected populations highlight that PD-L1 expression as a predictive biomarker is neither totally specificresponses have recurrently been reported in PD-L1-negative patients-nor sensitive-some PD-L1-positive patients do not benefit from these drugs. Such patients may be extremely informative and deeper examination of their immune profile is required.
challenge 4: patient eligibility
Given the peculiar safety profile of imAbs and the 'phase 1 registration trial' drug development strategy that is currently used, one can question whether the traditional phase 1 eligibility criteria should be unwounded, at least in the dose-expansion phase. Indeed, these agents are usually less toxic than conventional chemotherapies (Figure 1) , and irAEs can generally be managed with immunosuppressive agents (including steroids and anti-TNF-α antibodies). Patients with performance status ≥2, elevated LDH, low albumin, high number of metastatic sites or brain metastases are classically excluded from phase 1 trials based on prognostic scores that have been validated in this population [51] [52] [53] . However, these scores, based on data generated with cytotoxic drugs, might not suit to imAbs. Indeed, responses and clinical benefit have been observed with imAbs in patients with brain metastases, without any toxicity increase [54, 55] . Also, no additional toxicity was observed in patients with elevated LDH receiving tremelimumab [25] , in PS2 patients treated by BMS-936559 [4] or in urothelial bladder cancer patients with poor prognostic factors treated by atezolizumab [29] . Therefore, extending the inclusion criteria to a poorer prognosis, population might make sense for imAbs. However, this would better take place in dedicated expansion cohorts, once the toxicity profile of the investigational drug has been well characterized through the dose-escalation phase and through one safety expansion cohort.
Overall, in a context where most imAbs phase 1 trials aim at becoming registration trials, we may consider unwinding the eligibility criteria after completion of the dose-escalation phase and one safety expansion cohort. This would allow not only confirming the dose recommended for further studies directly in patients who would be more representative of all-comers oncology patients, but also speeding up recruitment and expediting drug development. challenge 5: PK and PD pharmacokinetics So far, clinically active imAbs have been immunoglobulins (Igs) (or antibodies). They are composed of two highly specific antigen-binding sites (located in the complementary determining regions of the Fab, or fragment of antigen binding), and one constant region, the Fc portion, which can bind to Fcγ receptors. Although Igs can be classified into five groups according to their heavy chain (IgA, D, E, G and M), the vast majority of Igs in the human serum are IgGs: all approved antibodies and imAbs in development belong to this class. This common IgG backbone explains the relative similar PK profile between imAbs, including a dose-dependent C max and area under the curve, and a median half-life of 16 days (9-21 days; Table 3 ). Differences, however, exist between immunostimulating IgGs according to their isotype: if most imAbs are IgG1 (such as ipilimumab, atezolizumab or durvalumab), some are IgG2 or IgG4 (such as tremelimumab and nivolumab, respectively). This can have a dramatic impact on bioactivity, with IgG1 and IgG3 being classically more prone to cause natural killer cell-mediated antibody-dependent cell-mediated cytotoxicity and IgG4 being more efficient in the activation of the alternative complement pathway.
Also, PK of antibodies is much more complex than that of small molecules, with notably peculiar absorption, distribution and elimination profiles (reviewed in ref. [56] ). For example, the impossibility of an oral administration associated with limited solubility leads to feasibility challenges (such as a maximal administrable volume) for the intravenous (IV), intramuscular (IM), subcutaneous or intratumour (IT) administration. Also, peculiar characteristics of high-affinity antibodies, such as 'target-mediated elimination', may result in underestimation of the distribution volume at steady state [57] . Finally, mechanisms, such as receptor-mediated endocytosis, concentrationdependent half-life, recycling through the Brambell receptor (FcRn) and impact of the circulating soluble forms of the targeted surface molecules (e.g. soluble PD-L1), also complexify IgG PK characteristics [56, 58, 59] . All these parameters can result in interindividual PK variations, which can have an impact on the activity of imAbs and eventually patients' survival [60] . Also, having a very short half-life-like T-cell engaging bi-specific antibodies that do not contain any Fc fragment (e.g. the FDA approved aCD3xaCD19 blinatumomab)-sometimes offers an interesting PK characteristic to manage toxicity more efficiently [61] . Finally, although most imAbs are now fully human antibodies, a few cases of human anti-human antibodies have been described [30] . As immunogenicity can vary according to dose, duration of therapy and route of administration, this risk should not only be thoroughly monitored throughout phase 1 trials but also be taken into account in the choice of the recommended dose, schedule and route of administration.
Although the interpretation of PK characteristics could be very rich and hypothesis-generating for optimal schedules or routes of administration, PK data have unfortunately generally been minimally discussed in phase 1 manuscripts of imAbs. These could indeed be of highest interest in a context where toxicities cannot always guide the dose-escalation or doserecommendation process, where the administration schedule can vary from a single injection to continuous exposure, and where the drug delivery mode ranges from IV to IT administration. pharmacodynamics PD data have been reported in only a limited number of trials. Regarding target occupancy, the nivolumab [3] and the anti-PD-L1 BMS-936559 [4] trials reported, respectively, a median PD-1 and PD-L1 receptor occupancy of 64%-70%, but surprisingly the occupancy was the same for both anti-PD1/-PD-L1 molecules and from doses ranging from 0.1 up to 10 mg/kg. Which minimum degree of target modulation should be achieved and for which duration is still unknown. Immunological monitoring has also been reported in some trials, including CD4+ and CD8+ T-cell monitoring, as well as repeated dosage of cytokines of the innate or adaptive immune responses [29] . Such dynamic [62] could also lead to PD variability of imAbs has not been explored so far. Recent data suggest that some subsets of FcγR are critical for the function of specific imAb isotypes [63] [64] [65] . Therefore, knowledge and experience that has been obtained in PD characteristics of licenced antibodies should be exploited to optimize imAbs development. Overall, there is a stark contrast between the limited information on PK/PD data reported in phase 1 manuscripts of imAbs, and the profusion of knowledge regarding mechanisms of antibody-dependent cell cytotoxicity, variability of this effect according to the antibody isotype, the availability of the complement and the expression of the target, as well as interactions between immune effector cells. Deeper implementation of this knowledge into the PK/PD modelling would be of highest interest.
challenge 6: responses and efficacy assessment
Criteria for response evaluation with imAbs are currently the matter of intense work and debate. Initial phase 1 trials of imAbs have traditionally used the modified World Health Organization (mWHO) criteria (for ipilimumab development), or RECIST v1.0/v1.1 criteria (for anti-PD1/PD-L1 antibodies). More recently, immune-related response criteria (irRC) have been proposed to better assess the variety of responses that can be generated upon imAbs [66] . Very interesting novel improvements in irRC have been proposed and validated in MM patients treated with ipilimumab, including the reduction in the number of target lesions and unidimensional measurements [67, 68] . Should these findings be validated with other imAbs and in other tumour types, such simplified criteria would be useful in protocols evaluating imAbs. Interestingly, very unusual and peculiar patterns of response have been described, including dissociated responses, delayed responses and pseudo-progressions-the physiopathology of which is still unclear. irRC undoubtedly allows better taking into account the potential for an initial 'flare-up' or pseudo-progression at the tumour site, for the appearance of new non-target lesions as well as for the difference between kinetics of response observed between imAbs and cytotoxic therapy, but it is still insufficient to recapitulate all response profiles or clinical benefits that have been observed. Adequate statistical modelling of longitudinal data, including CT scans, metabolic imaging and markers of immune monitoring under imAbs therapy, should be developed. Also, alternative end points, such as disease control rate and tumour growth rate, could be implemented-especially considering the highly variable timing of response, ranging from 6 weeks to several months after treatment initiation, or even after treatment cessation [69, 70] . Also, alternative strategies, such as metabolic imaging or immunological monitoring, may bring interesting information as early as phase 1. Finally, conventional therapies proposed upon tumour progression after imAbs may generate dramatic tumour responses [71, 72] . Such delayed and unexpected efficacy could explain part of the discrepancy between progression free survival and overall survival in imAbs-treated patients, but are currently inconstantly taken into consideration within phase 1 immunotherapy trial assessments.
future challenges
Overcoming primary and secondary resistance to imAb monotherapy is probably the biggest challenge in onco-immunology currently. Finding synergistic combinations and developing novel settings of drug administration are probably the ways to address these issues. The immune system is a tightly regulated balance and combining imAbs may require some 'fine-tuning' regarding the dose and schedule of administration, in order to avoid bolting the immune system. It is anticipated that most combinations of two imAbs will have to face toxicity challenges-as illustrated by the high rate of severe toxicities observed in the combinations of ipilimumab and nivolumab [13, 14, 47] . Combination of one imAb with another anticancer agent also raises questions regarding the optimal sequence, dose and schedule of each agent. For example, the phase 1 trial evaluating the combination of ipilimumab + vemurafenib [73] was terminated early for a high rate of G3-4 liver toxicities (in four and three out of six patients, at both doses that were tested, respectively), although these were asymptomatic and reversible. The phase 1 study associating ipilimumab with nivolumab [14] also displayed high rates of G3-4 drug-related toxicities and DLTs (53% and 21% of patients, respectively), but these AEs were manageable and similar to those experienced with monotherapy. Combinations with non-immunological anticancer agents should also be carefully designed, using flexible designs regarding doses, schedules and treatment management. In such trials, the most efficient drug might be administered at its best active dose, whereas the most experimental drug may be combined according to its monotherapy PK/PD profile (e.g. favouring intermittent administration at maximal dose, for drugs whose activity is peak-related, and favouring continuous administration at the lowest dose producing the desired PK/PD effect, for drugs whose activity is time-related). Importantly, all combination protocols should include provisions for dose de-escalation or prolonged treatment interruptions.
Most importantly, increased efficacy associated with lower toxicity could be achieved with imAbs by using specific administration routes such as local IT injections. This in situ immunization strategy is currently explored in an increasing number of phase 1 trials [74] . However, this is still a largely unexplored area and the ability of such strategy to lower toxicity while retaining some abscopal/synergistic activity will need to be demonstrated. Overall, phase 1 immunotherapy trials need to be innovative and use flexible designs to be able to adjust for any unexpected toxicity, or benefit.
conclusion
Considering their impressive and durable activity in selected tumour types associated with generally limited and manageable toxicity, imAbs are currently emerging as game-changers in cancer therapy. It is therefore crucial to optimize and expedite their development. Although this review has focused on phase 1 development of anti-CTLA-4 and anti-PD1/PD-L1 agents only, lessons learnt should benefit to the development of the plethora of other imAbs (agonists or antagonists), which are now being actively developed, including agents targeting KIR, ICOS, OX40, GITR, CD137 or CD27. We hope that some key information that has inconstantly been reported so far-including PK/PD data, and rationale for dose recommendation-will undergo more comprehensive analysis in future trials. Although these latter parameters might look simple as all imAbs are IgG antibodies, the reality is much more complex and several important PK/PD characteristics or the impact of FcγR binding within the tumour bed has been dramatically underexplored. Finally, considering the cost of imAbs and the economic challenge of reimbursement by health regulatory authorities and/or health insurances, there is now room for equivalence studies, comparing several doses, schedules and routes of administration, in order to minimize the number of per-patient administrations required to obtain an optimal immunostimulatory effect. disclosure
